Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. · 2019
Read Targeting PI3K in cancer: mechanisms and advances in clinical trials. by Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6379961.txt.
Introduction
Yang and co-authors present a review in Molecular Cancer on targeting the PI3K pathway in cancer. This signaling chain controls cell growth, movement, survival, and blood vessel formation. It goes wrong in nearly all human cancers, which makes it a prime drug target.
The review sorts inhibitors into dual PI3K/mTOR blockers, pan-PI3K drugs, and isoform-specific drugs. It tracks each class through clinical trials, noting where tumor growth slowed. Idelalisib, a delta-specific drug, was the first to win FDA approval. The authors also explain how tumors build resistance to these drugs. They close with strategies to restore drug response.
Catalog record
| CREATOR | Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 124 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |